Is Pacific Biosciences of California (PAC) stock a good buy?
Pacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $51.67, Pacific Biosciences of California has a forecasted upside of 222.5% from its current price of $16.02.
What is PCI Biotech’s policy on forward-looking statements?
PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
How much did PacBio make in Q4 2021?
MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million for its fourth quarter ended December 31, 2021.
What's new at pharmacyte biotech?
LAGUNA HILLS, Calif., December 08, 2021--PharmaCyte Biotech successfully complete the cytochrome P450 site of integration DNA sequencing assay required by the FDA to lift the clinical hold. LAS VEGAS, November 30, 2021--PharmaCyte Biotech launches its malignant ascites program with commencement of a pivotal preclinical study.
Is Pacific Biosciences stock a buy?
Pacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Why is Pacb stock dropping?
PacBio stock is falling today because the company reported unaudited fourth-quarter revenue that reached just $36 million. Image source: Getty Images. Compared to the prior-year period, revenue soared 33%.
Is Pacific Biosciences publicly traded?
Pacific Biosciences Announces Pricing of Initial Public Offering of Common Stock. the NASDAQ Global Select Market under the ticker symbol “PACB”. the offering.
Does Pacific Biosciences pay dividends?
PACB does not currently pay a dividend.
Will Pacb stock go up?
Stock Price Forecast The 6 analysts offering 12-month price forecasts for Pacific Biosciences of California Inc have a median target of 16.50, with a high estimate of 27.00 and a low estimate of 6.00. The median estimate represents a +269.54% increase from the last price of 4.47.
Who bought Pacific Biosciences?
Illumina, Inc.On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019.
What does Pacific Biosciences of California do?
About Pacific Biosciences of California Inc Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.
How many employees does Pacific Biosciences have?
Pacific Biosciences corporate office is located in 1305 O'brien Dr, Menlo Park, California, 94025, United States and has 667 employees. pacific biosciences of california , inc.
What is the difference between PacBio and Illumina?
PacBio provides longer read length than Illumina's short-length reads. Longer reads offer better opportunity for genome assembly, structural variant calling. It is not worse than short reads for calling SNP/indels, quantifying transcripts. Sounds like PacBio can do whatever Illumina platform can offer.
Recently Viewed Tickers
Pacific Biosciences of California Inc
Visit a quote page and your recently viewed tickers will be displayed here.
What is the PACB symbol?
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The firm's products and services include PacBio sequel system, consumables, analytical software and single molecule real-time (SMRT) compatible products.
How much money does Pacific Biosciences make?
Pacific Biosciences of California trades on the NASDAQ under the ticker symbol " PACB."
What is the official website of Pacific Biosciences?
How much money does Pacific Biosciences of California make? Pacific Biosciences of California has a market capitalization of $5.89 billion and generates $78.89 million in revenue each year. The biotechnology company earns $29.40 million in net income (profit) each year or ($0.43) on an earnings per share basis.
What is Pacific Biosciences?
The official website for Pacific Biosciences of California is www.pacb.com.
Where is Pacific Biosciences located?
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The firm's products and services include PacBio sequel system, consumables, analytical software and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Does Pacific Biosciences pay dividends?
Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected].
What is governance score?
Pacific Biosciences of California does not currently pay a dividend.
What is the environmental score?
The governance score is comprised of weighted key performance indicators related to leadership, management, and business model.
Why did Illumina propose the nuclear option?
The environmental score is comprised of weighted key performance indicators related to natural capital, innovation, and climate change.
What are investors enthusiastic about?
Illumina just proposed the nuclear option to earn regulatory approval for its merger and keep its biggest competitor at bay.
How many articles has The Fool written?
Investors are enthusiastic about an analyst's upgrade of the stock.
Who is Pacific Biosciences?
The Fool has written over 200 articles on Pacific Biosciences of California.
Will scientific advances reward investors?
Pacific Biosciences is a leader in the latest generation of human DNA sequencing.
Is Pacific Biosciences The Best Biotech Stock To Buy In The Stock Market Today?
Incredible scientific advances could reward investors -- if they have the patience.
What is the name of the company that uses the HiFi sequencing system?
In the biotech world of genome sequencing, Illumina ( NASDAQ: ILMN) may be the undisputed market leader. But when it comes to shareholder returns in the past year, Pacific Biosciences of California Inc. ( NASDAQ: PACB) was one of the top performers, rewarding investors lavishly. For the uninitiated, Pacific Biosciences (or PacBio) is a biotechnology company that develops gene sequencing systems.
What is a pacbio?
Last month, PacBio announced a multi-year partnership with Invitae ( NYSE: NVTA) to expand its genome testing capabilities using PacBio’s HiFi sequencing system. Invitae CEO Sean George said that this deal will enable his company “ to develop a new generation of innovative whole genome-based offerings. ” George expects the collaboration will help make whole-genome sequencing for diagnosing diseases and guiding healthcare decisions “ affordable and accessible to all patients who can benefit from in-depth, full genome information. “
How many SMRT systems are there in PacBio?
Also, PacBio is a leader in high-fidelity (HiFi) DNA-sequencing platforms, which can produce accurate and complete data that researchers can use to study genetic diseases. The aim of this technology is to give doctors a more comprehensive understanding of how genes contribute to human health.
How to close a modal window?
The company has been growing its installed base. At the end of 2020, it has sold a total of 203 systems. Of these 203, 35 were installed in the fourth quarter of 2020.
Does SoftBank invest in DNA sequencing?
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Is genome sequencing a biotechnology company?
“ This strategic investment by SoftBank validates our leadership position in the long-read DNA sequencing market and enables us to further accelerate our growth strategies, ” PacBio CEO Christian Henry said in a press release.
What is the partnership between PCI and Olix?
By and large, genome sequencing is a highly potent area to be in the biotechnology sector. However, the real question here is, should investors initiate a position in PACB stock now? Before we dive in, it’s also worth noting that the company has come a long way to reach where it is today. Since the merger attempt with Illumina fell off, things haven’t looked pretty well for the company until a change of leadership and its recently launched product.
What is PCI Biotech?
OliX Pharmaceuticals and PCI Biotech will combine their know-how and technology platforms to explore synergies and further partnership on dermatology and other applications. The partnership is governed by a research collaboration agreement, under which the collaborators will perform an extensive evaluation of technology compatibility and synergy based on OLX104C (Androgenic Alopecia) preclinical studies. The companies will evaluate results achieved from this research collaboration to explore the potential for further development and partnership. Commenting on the announcement, Dong Ki Lee, CEO of OliX Pharmaceuticals said: “We are very excited to collaborate with PCI Biotech. Combining our proprietary asiRNA platform with PCI’s leading fimaNAc delivery technology will significantly accelerate our efforts to bring our dermatological RNAi programs to the clinic. We also expect to expand the area of application to our cancer immunotherapy pipeline and mRNA vaccines developed by our subsidiary, mCureX, in the near future.” PCI Biotech’s CEO, Per Walday, added: “We are very pleased to initiate this exciting collaboration with OliX Pharmaceuticals. This collaboration builds on the strong potential of our intracellular delivery platform technology for nucleic acid based therapies, within a therapeutic field of good technological fit. Combining the leading technologies of OliX Pharmaceuticals and PCI Biotech may lead to new promising applications and we look forward to the collaboration.” About OliX PharmaceuticalsOliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases. For more information, please visit: https://www.olixpharma.com About PCI BiotechPCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialization of novel therapies for the treatment of cancer through its innovative photochemical internalization (PCI) technology platform, for intracellular delivery. PCI induces triggered endosomal release that enables drugs to reach intracellular therapeutic targets. Currently, PCI Biotech is working on three programs: fimaChem (enhancement of chemotherapeutics for localized treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). For more information, please visit: www.pcibiotech.com Contact Information: OliX Pharmaceuticals Media ContactKelly Kim / CommunicationsPhone: +82 10 4220 2801E-Mail: [email protected] PCI Biotech Holding ASA Per Walday, CEO Mobile: +47 917 93 429 E-Mail: [email protected] Forward-looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
When is PCI meeting 2021?
Oslo (Norway), 31 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company , today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new US patent will be granted early June 2021. The US patent covers the use of fimaVacc in combination with immune checkpoint inhibitors (ICIs). The use of ICIs has revolutionised cancer immunotherapy, as this class of drugs may induce long-lasting effects in those patients responding to treatment. Unfortunately, most patients do not respond to ICI therapy and different treatment combination strategies are explored with the aim to increase the number of patients responding. Combining ICIs with therapeutic cancer vaccines that induce relevant immune responses against the tumour cells is regarded as one of the most promising strategies. The patent that soon will be granted in the US covers the use of PCI Biotech’s fimaVacc vaccination technology in combination with important classes of ICIs and an important type of immunological adjuvants (a class of so-called Toll like receptor agonists). “Increasing the response rates to ICI’s is one of the pharma industry’s main priorities in cancer and therapeutic cancer vaccination is a rational approach to this aim. The fimaVacc technology has delivered encouraging immune responses in early phase clinical trials and this US patent provides relevant intellectual property for the further development of this technology.“ said Dr. Per Walday, CEO of PCI Biotech. As part of PCI Biotech’s strategy for applying the PCI technology for therapeutic cancer vaccines, several global patent applications were filed in 2013-2016. Today’s announced US patent secure protection until 2036 and this patent application is still pending in Europe and key Asian markets. About fimaVacc This novel vaccine technology applies a unique mode of action, triggered endosomal release of antigens or antigen-encoding nucleic acids, to enhance immune responses essential for therapeutic cancer vaccines as well as for several types of vaccines against viral and parasitic infections. fimaVacc works in synergy with several other state-of-the-art vaccination technologies, and is especially effective in combination with some types of TLR agonists. The fimaVacc programme aims to enhance the cellular immune responses that are important for the therapeutic and prophylactic effect of vaccines, and the fimaVacc technology has proven excellent preclinical efficacy with protein- and peptide-based vaccines. The technology has shown particularly strong CD8 T-cell immune responses, which are important for therapeutic vaccination, as well as enhanced helper (CD4) T-cell and antibody responses. PCI Biotech successfully translated the vaccination technology into humans through a Phase I study in healthy volunteers that was completed in May 2019. The study covered more than 90 subjects and established the tolerability of fimaVacc across a wide range of doses. The immune results provided proof-of-concept and demonstrates fimaVacc‘s potential to enhance overall T-cell responses, by demonstrating improvement of the immunogenicity of vaccines in healthy volunteers. The results from the successful Phase I proof of concept study for the fimaVacc technology were recently published in Frontiers in Immunology, a high impact immunology journal. The article title is "Photochemical internalization enhanced vaccination is safe, and gives promising cellular immune responses to an HPV peptide-based vaccine in a phase I clinical study in healthy volunteers” and the publication is available through this link: https://www.frontiersin.org/articles/10.3389/fimmu.2020.576756/full Effective induction of proper cellular immune responses will be critical to realise the huge potential of therapeutic cancer vaccines, and is also important for vaccination against some viral and parasitic infections. With present technologies vaccines often fail to generate such responses, and especially cytotoxic T-cell responses are often inappropriate. Insufficient delivery of vaccine antigens to the appropriate presentation pathway in the immune cells may be one of the main reasons for weak cytotoxic T-cell responses. The fimaVacc technology has the potential to effectively enhance vaccine presentation through these pathways. Contact information: Per Walday, CEO [email protected]: +47 917 93 429 About PCI Biotech PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For further information, please visit: www.pcibiotech.com Forward-looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
When will PCI Biotech report 2021?
PCI Biotech: Notice of Annual General Meeting 2021. Oslo, Norway 7 May 2021 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 28 May 2021 at 10:00am (CEST).
What is PCI in cancer?
Oslo, Norway, 30 April 2021 - PCI Biotech’s (OSE: PCIB) first quarter 2021 interim report will be released on 7 May 2021 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com. A results presentation (in English) will be held through a live webcast at 08.30 CEST the same day. The webcast can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation. It will be possible to post written questions through the webcast console or through a teleconference facilitated for investors intending to ask questions verbally during the Q&A session. For further information, please contact:Ronny Skuggedal, CFOEmail: [email protected]: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For further information, please visit: www.pcibiotech.com Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Forward-looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Where is the annual meeting of PCI Biotech held?
PCI is applied to three distinct anticancer paradigms : fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
When will PCIB be granted?
Oslo, Norway 7 May 2021 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 28 May 2021 at 10:00am (CEST). Due to the extraordinary situation with the Covid-19 pandemic, the Board has found it necessary to urge shareholders to exercise their shareholder rights through advance votes by electronic communication via VPS Investor Services or to vote by proxy prior to the meeting and not attend the annual general meeting in person. The notice including attendance and proxy forms will be mailed to all shareholders with known address. The complete notice, including the board of directors’ proposed resolutions for the items listed on the agenda, the recommendation of the nomination committee, the annual accounts and annual report for the financial year 2020, including the corporate governance report for 2020 and the guidelines for remuneration of executive management are attached to this notification and will also be made available at PCI Biotech's corporate website www.pcibiotech.com. The notice including attendance and proxy forms, the board of directors’ proposed resolutions for the items listed on the agenda and the proposal from the nomination committee are attached hereto in both English and Norwegian. For further information, please contact: Ronny Skuggedal, CFO, E-mail: [email protected]: +47 67 11 54 00 Mobile: +47 94 00 57 57 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Attachments PCI Biotech Holding ASA Innkalling GF 28 mai 2021 PCI Biotech Holding ASA Forslag til vedtak GF 28 mai 2021 PCI Biotech Holding ASA Notice of AGM 28 May 2021 PCI Biotech Holding ASA Proposed resolutions for the AGM 28 May 2021 PCI Biotech Proposal from the Nomination Committee 2021 PCI Biotech Remuneration Policy PCI Biotech Holding ASA Annual Report 2020
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
Patent and Trademark Office (USPTO) has informed the company that a new US patent will be granted early June 2021.
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
LAS VEGAS, February 14, 2022--PharmaCyte Biotech updates status of its Investigational New Drug Application to the FDA.
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
LAS VEGAS, January 06, 2022--PharmaCyte Biotech Chief Executive Officer to present at the H.C. Wainwright BioConnect Conference.
Could The Solid State plc (LON:SOLI) Ownership Structure Tell Us Something Useful?
LAS VEGAS, January 04, 2022--PharmaCyte Biotech biocompatibility study proves that its capsule material is not toxic for the encapsulated cells inside the capsules.
Is Now An Opportune Moment To Examine Solid State plc (LON:SOLI)?
The big shareholder groups in Solid State plc ( LON:SOLI ) have power over the company. Insiders often own a large...
What is CM24 antibody?
While Solid State plc ( LON:SOLI ) might not be the most widely known stock at the moment, it received a lot of...
How much cash does Purple Biotech have?
CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1 study followed by a phase 2 for the treatment ...
How much was SG&A in 2020?
As of December 31, 2020, Purple Biotech had cash and cash equivalents and short- and long-term deposits of $60.8 million, compared to $4.4 million at December 31, 2019. Purple Biotech believes that its cash position will provide sufficient resources for its currently anticipated ongoing needs until fiscal year 2024.
What is IRS2 in CRC?
SG&A Expenses were $6.3 million, compared to $6.1 million for the year ended December 31, 2019.
How much was the operating loss in 2019?
IRS2 is a known downstream effector of IGF-1 receptors, which regulate cell growth and proliferation. The updated in vitro and in vivo data show the importance of the expression of IRS2 in the development, survival and growth of CRC brain metastasis.
